Bristol-Myers Squibb Company has become the second large pharma company in recent weeks to invest in treatments for fibrosis with the signing of an option agreement to acquire Galecto Biotech AB of Denmark which has an early stage product for idiopathic pulmonary fibrosis (IPF).
